Vanda Pharmaceuticals Inc... (VNDA)
Vanda Pharmaceuticals Statistics
Share Statistics
Vanda Pharmaceuticals has 58.32M shares outstanding. The number of shares has increased by 1.34% in one year.
| Shares Outstanding | 58.32M |
| Shares Change (YoY) | 1.34% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 73.65% |
| Shares Floating | 54.39M |
| Failed to Deliver (FTD) Shares | 16.09K |
| FTD / Avg. Volume | 2.55% |
Short Selling Information
The latest short interest is 3.29M, so 5.64% of the outstanding shares have been sold short.
| Short Interest | 3.29M |
| Short % of Shares Out | 5.64% |
| Short % of Float | 5.95% |
| Short Ratio (days to cover) | 6.21 |
Valuation Ratios
The PE ratio is -14.74 and the forward PE ratio is 22.12. Vanda Pharmaceuticals's PEG ratio is 0.02.
| PE Ratio | -14.74 |
| Forward PE | 22.12 |
| PS Ratio | 1.4 |
| Forward PS | 0.7 |
| PB Ratio | 0.52 |
| P/FCF Ratio | -17.14 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Vanda Pharmaceuticals Inc. has an Enterprise Value (EV) of 115.73M.
| EV / Earnings | -6.12 |
| EV / Sales | 0.58 |
| EV / EBITDA | -2.85 |
| EV / EBIT | -2.85 |
| EV / FCF | -7.12 |
Financial Position
The company has a current ratio of 4.39, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.39 |
| Quick Ratio | 4.37 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.24 |
| Cash Flow / Debt | -1.27 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.04% and return on capital (ROIC) is -6.09%.
| Return on Equity (ROE) | -0.04% |
| Return on Assets (ROA) | -0.03% |
| Return on Capital (ROIC) | -6.09% |
| Revenue Per Employee | $540,141.3 |
| Profits Per Employee | $-51,358.7 |
| Employee Count | 368 |
| Asset Turnover | 0.3 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.02M |
| Effective Tax Rate | 0.18 |
Stock Price Statistics
The stock price has increased by 14.36% in the last 52 weeks. The beta is 0.69, so Vanda Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.69 |
| 52-Week Price Change | 14.36% |
| 50-Day Moving Average | 4.66 |
| 200-Day Moving Average | 5.02 |
| Relative Strength Index (RSI) | 46.18 |
| Average Volume (20 Days) | 630.18K |
Income Statement
In the last 12 months, Vanda Pharmaceuticals had revenue of 198.77M and earned -18.9M in profits. Earnings per share was -0.33.
| Revenue | 198.77M |
| Gross Profit | 198.77M |
| Operating Income | -40.66M |
| Net Income | -18.9M |
| EBITDA | -40.66M |
| EBIT | -40.66M |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
The company has 102.32M in cash and 12.36M in debt, giving a net cash position of 89.96M.
| Cash & Cash Equivalents | 102.32M |
| Total Debt | 12.36M |
| Net Cash | 89.96M |
| Retained Earnings | -174.29M |
| Total Assets | 656.2M |
| Working Capital | 338.91M |
Cash Flow
In the last 12 months, operating cash flow was -15.76M and capital expenditures -490K, giving a free cash flow of -16.25M.
| Operating Cash Flow | -15.76M |
| Capital Expenditures | -490K |
| Free Cash Flow | -16.25M |
| FCF Per Share | -0.28 |
Margins
Gross margin is 100%, with operating and profit margins of -20.46% and -9.51%.
| Gross Margin | 100% |
| Operating Margin | -20.46% |
| Pretax Margin | -11.53% |
| Profit Margin | -9.51% |
| EBITDA Margin | -20.46% |
| EBIT Margin | -20.46% |
| FCF Margin | -8.17% |
Dividends & Yields
VNDA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.02% |
| FCF Yield | -5.93% |
Analyst Forecast
The average price target for VNDA is $16.5, which is 251.1% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.5 |
| Price Target Difference | 251.1% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 1.76 |
| Piotroski F-Score | 3 |